Bharat Biotech, the maker of the Covaxin vaccine, has overcome initial hiccups at its Bengaluru facility and is on track to go ahead as planned, said V K Paul, chairman of the national Covid task force, and member-health, NITI Aayog.
Paul said the company has added two facilities in Ankleshwar and Bengaluru as part of its expansion plans. While Ankleshwar has started production, according to schedule, there were some issues with initial stabilisation due to unforeseen circumstances.
“Production was a little behind expectations, but issues have been addressed. The production it had planned will be achieved,” said Paul.
Bharat Biotech is hoping to manufacture 1 billion doses per annum by the end of this year.
PRESS24 NEWS has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to PRESS24 NEWS.
Disclaimer: This post has been auto-published from an agency/news feed without any modifications to the text and has not been reviewed by an editor.